Arch Therapeutics Inc Revenue Growth Rates (ARTH), Current and Historic Growth - CSIMarket
CSIMarket Company Name, Ticker, Customers, else..
 


• Revenue Y/Y
• Op. Income Y/Y
• Cop. Income Y/Y
• Net Income Y/Y
• Eps Cop. Y/Y
• Eps Net Y/Y
• Free Cash Flow Y/Y
• Cash Flow Y/Y
• Capex Y/Y
• Sales Y/Y Annual
Arch Therapeutics Inc   (ARTH)
 

ARTH's Revenue Growth by Quarter and Year

Arch Therapeutics Inc 's Revenue results by quarter and year



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

ARTH Revenue (in millions $) FY 2024 FY 2023 FY 2022 FY 2021
4th Quarter September -
3rd Quarter June 0.03
2nd Quarter March 0.03
1st Quarter December 0.05
FY 0.11





ARTH Revenue third quarter 2024 Y/Y Growth Comment
Arch Therapeutics Inc reported Revenue surge of 209.13% year on year in the third quarter 2024, to $ 0.03 millions, this is lower than Arch Therapeutics Inc 's recent average Revenue surge of 112307.01%.

Looking into third quarter 2024 results within Medical Equipment & Supplies industry 7 other companies have achieved higher Revenue growth. While Arch Therapeutics Inc ' s Revenue doubling of 209.13% ranks overall at the positon no. 127 in the third quarter 2024.


ARTH Revenue ( Y/Y Growth %) 2024
 2023 2022 2021
4th Quarter September - - - -
3rd Quarter June 209.13 % 0 % - -
2nd Quarter March 50 % -98 % 9900 % -
1st Quarter December 400 % - - -
FY   - -92.08 % 741.67 % -

Financial Statements
Arch Therapeutics Inc 's third quarter 2024 Revenue $ 0.03 millions ARTH's Income Statement
Arch Therapeutics Inc 's third quarter 2023 Revenue $ 0.01 millions Quarterly ARTH's Income Statement


ARTH Revenue (Quarter on Quarter Growth %)

 2024
 2023 2022 2021
4th Quarter September - 300 % - -
3rd Quarter June 3.04 % -50 % -99 % -
2nd Quarter March -40 % 100 % - -90.91 %
1st Quarter December 25 % - - -
FY (Year on Year)   - -92.08 % 741.67 % -


Back to ARTH Growth rate Comparisons >> Back to ARTH Growth rate Comparisons >>


Revenue third quarter 2024 Y/Y Growth Company Ranking
Within: No.
Medical Equipment & Supplies Industry #8
Healthcare Sector #58
Overall #127

Revenue Y/Y Growth Statistics
High Average Low
1000027.8 % 112307.01 % -99.75 %
(Jun 30 2023)   (Sep 30 2023)
Revenue third quarter 2024 Y/Y Growth Company Ranking
Within: No.
Medical Equipment & Supplies Industry #8
Healthcare Sector #58
Overall #127
Revenue Y/Y Growth Statistics
High Average Low
1000027.8 % 112307.01 % -99.75 %
(Jun 30 2023)   (Sep 30 2023)

Revenue by Quarter for the Fiscal Years 2021, 2022, 2023, 2024

Arch Therapeutics Inc 's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
249892.01 % 22614.98 % -100 %
(Sep 30 2022)  


ARTH's III. Quarter Q/Q Revenue Comment
In the III. Quarter 2024 Arch Therapeutics Inc disclosed growth in Revenue from the second quarter by 3.04% to $ 0.03 millions, from $ 0.03 millions achived in the previous reporting period.

Within Medical Equipment & Supplies industry 151 other companies have achieved higher Revenue quarter on quarter growth. While Arch Therapeutics Inc 's Revenue growth quarter on quarter, overall rank is 3002.


Revenue Q/Q Growth Company Ranking
Within: No.
Medical Equipment & Supplies Industry #152
Healthcare Sector #467
Overall #3002
Revenue Q/Q Growth Company Ranking
Within: No.
Medical Equipment & Supplies Industry #152
Healthcare Sector #467
Overall #3002
Revenue Q/Q Growth Statistics
High Average Low
249892.01 % 22614.98 % -100 %
(Sep 30 2022)  


ARTH's III. Quarter Q/Q Revenue Comment
In the III. Quarter 2024 Arch Therapeutics Inc disclosed growth in Revenue from the second quarter by 3.04% to $ 0.03 millions, from $ 0.03 millions achived in the previous reporting period.

Within Medical Equipment & Supplies industry 151 other companies have achieved higher Revenue quarter on quarter growth. While Arch Therapeutics Inc 's Revenue growth quarter on quarter, overall rank is 3002.


Arch Therapeutics Inc 's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Jun 30 2024)		 12 Months Ending
(Mar 31 2024)		 12 Months Ending
(Dec 31 2023)		 12 Months Ending
(Sep 30 2023)		 12 Months Ending
(Jun 30 2023)
Cumulative Revenue 12 Months Ending $ 0.15 $ 0.13 $ 0.12 $ 0.08 $ 0.04
Y / Y Revenue Growth (TTM) 292.23 % 324.64 % -88.66 % -92.54 % -96.28 %
Year on Year Revenue Growth Overall Ranking # 12 # 8 # 4 # 23 # 27
Seqeuential Revenue Change (TTM) 13.5 % 13.19 % 52.3 % 100.47 % 22.87 %
Seq. Revenue Growth (TTM) Overall Ranking # 1976 # 2071 # 1157 # 23 # 17


Cumulative Revenue growth Comment
Assuming the Arch Therapeutics Inc 's fiscal year would have ended in Jun 30 2024, Arch Therapeutics Inc would have reprted above average annual Revenue surge of 292.23% year on year, of $ 0 millions.
This marks a slow-down of the companys growth trends and from the 324.64% surge in Mar 31 2024.

Among companies within the Healthcare sector 3 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 8 to 12.

Revenue TTM Y/Y Growth Company Ranking
Within: No.
Medical Equipment & Supplies Industry # 112
Healthcare Sector # 4
Overall # 12

Revenue TTM Y/Y Growth Statistics
High Average Low
1444.64 %
 209.51 %
-99.55 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 112
Sector # 342
S&P 500 # 1976
Cumulative Revenue growth Comment
Assuming the Arch Therapeutics Inc 's fiscal year would have ended in Jun 30 2024, Arch Therapeutics Inc would have reprted above average annual Revenue surge of 292.23% year on year, of $ 0 millions.
This marks a slow-down of the companys growth trends and from the 324.64% surge in Mar 31 2024.

Among companies within the Healthcare sector 3 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 8 to 12.


Revenue TTM Y/Y Growth Company Ranking
Within: No.
Medical Equipment & Supplies Industry # 112
Healthcare Sector # 4
Overall # 12

Revenue TTM Y/Y Growth Statistics
High Average Low
1444.64 %
209.51 %
-99.55 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 112
Sector # 342
S&P 500 # 1976




Other Revenue Growth
Medical Equipment & Supplies Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
ARTH's Revenue Growth Ratio versus Medical Equipment & Supplies Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth




Companies with similar Revenue surge for the quarter ending Jun 30 2024 within Healthcare SectorY/Y Change %Revenue for the quarter ending Jun 30 2024
Generation Bio Co 364.89%$ 364.886 millions
Uniqure N v 359.37%$ 359.372 millions
Tg Therapeutics Inc 357.05%$ 357.049 millions
Cardio Diagnostics Holdings Inc 356.23%$ 356.232 millions
C4 Therapeutics Inc 350.68%$ 350.676 millions
Celularity Inc 312.22%$ 312.219 millions
Spero Therapeutics Inc 275.44%$ 275.442 millions
Molecular Partners Ag271.35%$ 271.345 millions
Siga Technologies Inc271.05%$ 271.049 millions
Biofrontera Inc 260.94%$ 260.944 millions
Sage Therapeutics Inc 249.80%$ 249.798 millions
Inhibrx Biosciences Inc 233.33%$ 233.333 millions
Pavmed Inc 231.00%$ 231.003 millions
Ardelyx inc 227.86%$ 227.865 millions
Lipocine Inc 226.22%$ 226.225 millions
Verve Therapeutics Inc 219.73%$ 219.732 millions
Anaptysbio Inc 217.08%$ 217.081 millions
Nuo Therapeutics Inc 208.69%$ 208.688 millions
Sab Biotherapeutics Inc 207.70%$ 207.698 millions
Esperion Therapeutics Inc 186.33%$ 186.334 millions
Omega Therapeutics Inc 181.16%$ 181.159 millions
Zymeworks Inc 174.82%$ 174.821 millions
Carisma Therapeutics Inc 158.34%$ 158.343 millions
Roivant Sciences Ltd 154.96%$ 154.957 millions
Northwest Biotherapeutics Inc153.73%$ 153.731 millions
Precision Biosciences Inc152.15%$ 152.150 millions
Sutro Biopharma Inc 146.89%$ 146.888 millions
Bioxcel Therapeutics Inc 141.58%$ 141.575 millions
Blueprint Medicines Corporation139.98%$ 139.981 millions
Ocugen Inc 135.26%$ 135.258 millions


About Arch Therapeutics Inc Revenue Growth Rates (ARTH), Current and Historic Growth - CSIMarket Analysis

How we calculate this

This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years). Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.

What’s included here

Company: Arch Therapeutics Inc (CIK 1537561).

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings → XBRL parse → normalization CSIMarket.com Database → growth calculations.
  • Accession: 0001493152-24-033091
  • Figures are derived from filed reports and may be restated; numbers are subject to revision.

Sources: Arch Therapeutics Inc ’s SEC filings (XBRL/Inline XBRL) and CSIMarket.com’s normalization & QA processes.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.